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Endochin-like quinolones (ELQs) potently inhibit the proliferation of Plasmodium,
Toxoplasma, Neospora, and Babesia by targeting the cytochrome b Qo and Qi sites
and interfering with oxidative phosphorylation and pyrimidine biosynthesis. The activities
of 14 different ELQs were assessed against B. besnoiti tachyzoites grown in human
foreskin fibroblasts (HFF) by quantitative real time PCR. The values for 50% proliferation
inhibition (IC50) of five ELQs were determined in a 3-days growth assay after an initial
screen of 12 ELQs at 0.01, 0.1, and 1µM. The IC50s of ELQ-121, -136, and -316 were
0.49, 2.36, and 7.97 nM, respectively. The IC50s of ELQs tested against B. besnoiti
were higher than IC50s previously observed for P. falciparum and T. gondii. However,
the B. besnoiti cytochrome b sequence and the predicted Qo and Qi ELQ binding
sites in the Toxoplasma, Neospora, and Besnoitia cytochrome b are virtually identical,
suggesting that the differences in ELQ susceptibility are not due to variations in the
substrate binding sites. TEM of ELQ-treated parasites primarily demonstrated alterations
within the parasite mitochondrion, profound thickening of the nuclear membrane, as well
as increased vacuolization within the tachyzoite cytoplasm. Long-term treatment assays
of intracellular B. besnoiti with ELQs for up to 20 days followed by the release of drug
pressure caused a substantial delay in parasite growth and proliferation while ELQs were
present, but parasite proliferation resumed days after ELQs were removed. Interestingly,
structural alterations persisted after ELQ removal and parasite proliferation was slowed.
These findings provide a basis for further in vivo studies of ELQs as therapeutic options
against B. besnoiti infection.
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INTRODUCTION
Besnoitia besnoiti is a cyst-forming coccidian parasite (1), which is closely related to Neospora
caninum and Toxoplasma gondii and is the causative agent of bovine besnoitiosis (2, 3). Bovine
besnoitiosis was originally restricted to endemic areas in Portugal, Spain, and South of France
(4). Lately, new outbreaks of the disease have been reported in other parts of Europe, including
Germany, Italy, Hungary, Croatia, Belgium, and Switzerland (2, 5). Due to the geographic
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expansion and increased number of cases, the European Food
Safety Authority (EFSA) has proclaimed besnoitiosis as a re-
emerging disease (6, 7).
Similar to other cyst-forming coccidian parasites, B. besnoiti
is suspected to have an indirect life cycle in which a carnivore
represents the definitive host and cattle as well as wild bovids
serve as intermediate hosts. Although cats have been shown to be
the definitive host of several other Besnoitia species (B. darlingi,
B. wallacei, B. orictofelisi, and B. neotomofelis), the definitive host
of B. besnoiti has not been identified (1).
Bovine besnoitiosis induces serious economic losses in terms
of reduced milk and meat production, infertility and sterility in
bulls, skin damage, poor body conditions, occasional abortions
in dams, premature slaughter, and deaths (2, 4). The formation
of dermal tissue cysts at the chronic stage is a hallmark of bovine
besnoitiosis, and causes dermal lesions, hair loss, hyperkeratosis,
hyperpigmentation and rather dramatic thickening, hardening
and folding or wrinkling of the skin, especially around the neck,
shoulders and rump. To date, none of the members of the genus
Besnoitia has been shown to infect humans (3).
The treatment options to tackle bovine besnoitiosis are
limited. The disease could be controlled by either culling an
infected animal or possibly prevented by vaccination and/or
chemotherapy (8). However, no vaccine against B. besnoiti is
licensed in Europe, and there are no effective drugs available to
date (6). Since several aspects of the biology of B. besnoiti are not
well-understood, targeted drug development against this disease
is far from becoming reality. Thus, repurposing of compounds
that are already licensed or under development is a faster way to
identify novel candidate therapeutics against B. besnoiti infection.
This has been demonstrated in studies on thiazolides (9), cationic
arylimidamides (10), bumped kinase inhibitors (BKIs), diclazuril
and decoquinate (11, 12), and buparvaquone (13).
Endochin-like quinolones (ELQs) are derived from endochin,
a 4(1H)-quinolone that is a cytochrome bc1 complex inhibitor,
similar to atovaquone, or buparvaquone. Inhibitors of the
mitochondrial electron transport chain can bind to the oxidative
Qo site or the reducing Qi site of cytochrome b, prevent
oxidative phosphorylation and cause deprivation of essential
molecules and the generation of reactive oxygen species (ROS)
(14). Disruption of the mitochondrial electron transport chain
of parasites has devastating consequences, and has been the
focus of the development of anti-parasitic drugs for decades (15).
Endochin had been shown to exhibit promising activity against
experimental avian malaria (16), but was unstable when exposed
to murine, rat, and human microsomes, prohibiting its clinical
use. However, ELQs with aromatic side chains at position three
were shown to exhibit IC50s in the range of 0.1 nM against
Plasmodium falciparum in vitro (17). Doggett et al. (18) and
Nilsen et al. (19) reported the synthesis of novel endochin analogs
with a diphenylether side chain at the third position, and various
substitutions at the quinolone ring at position 5, 6, or 7. These
include ELQ-300 and ELQ-316, which confer Qi site inhibition,
and ELQ-400 (20), which has been reported to target both Qo
and Qi sites of cytochrome b of S. cerevisiae and potentially other
organisms (21). ELQ-316 inhibited T. gondii proliferation in vitro
at sub-nanomolar concentrations. The drug was highly effective
in a murine acute disease model, and reduced the Toxoplasma
cyst burden in a model of latent infection by 76–80% (18, 22).
In order to improve the bioavailability and water-solubility of
ELQs, ethyl carbonate prodrugs were synthesized (23). ELQ-334
is such a prodrug of ELQ-316 that is much better absorbed and
yields a 6-fold increase in ELQ-316 exposure after oral uptake and
metabolization. More recently, a series of ELQs were reported to
exhibit promising in vitro activity againstN. caninum tachyzoites
(24). ELQ-400 treatment in mice experimentally infected with
N. caninum tachyzoites lead to significantly reduced parasite
burden (25). ELQ-334 treatment ofN. caninum infected pregnant
mice did not reduce the cerebral parasite burden in the dams,
but inhibited vertical transmission and clinical signs in newborn
pups and in the dams (24). The experimental efficacy of ELQs as
well as the fact that they have been optimized to avoid targeting
the human cytochrome bc1 complex renders them promising
anti-parasitic compounds (26).
In this study, we assessed the in vitro activities of 12 distinct
ELQ analogs against the B. besnoiti strain Bb Lisbon. The
most active ELQs against this parasite (ELQ-121 and ELQ-
136), as well as ELQ-316 and its prodrug ELQ-334 were
studied for their parasiticidal vs. parasitostatic activities, and
ultrastructural alterations induced by these compounds within
B. besnoiti tachyzoites were investigated by transmission electron
microscopy (TEM).
MATERIALS AND METHODS
Tissue Culture Media, Biochemicals, and
Drugs
If not stated otherwise, all tissue culture media were purchased
fromGibco-BRL (Zürich, Switzerland), and biochemical reagents
were from Sigma (St. Louis, MO). ELQs were obtained from
VA Portland Healthcare System Department of Research and
Development Service in Portland, Oregon, USA, and were
synthesized as previously described (22). For in vitro studies
the compounds were stored as 10mM stock solutions in DMSO
at−20◦C.
Host Cell Cultivation and Parasite Cultures
Human foreskin fibroblasts (HFF) were maintained as described
earlier (24, 25). The B. besnoiti isolate Bb Lisbon was obtained,
following published procedures (27), from a naturally occurring
chronic case of bovine besnoitiosis. Bb Lisbon tachyzoites
were maintained by serial passages in HFF in culture medium
(DMEM containing 10% FCS). Tachyzoites were harvested by
removal of the cell layer with a cell scraper, repeated passage
through a 25G needle, and Sephadex G25 chromatography as
described (13).
Primary in vitro Screening
In a primary screen, a small library of 14 ELQs (Table 1)
was assessed for their effects on in vitro proliferation of Bb
Lisbon tachyzoites. Six-well tissue culture plates were seeded
with 1.2 × 105 HFF per well and were incubated for 3
days at 37◦C and 5% CO2. Prior to infection of confluent
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TABLE 1 | Structures of the 14 ELQ compounds and IC50 values measured against Besnoitia besnoiti, Neospora caninum and Toxoplasma gondii tachyzoites.
ELQ MW
(g/mol)






100 287.4 -C7H15 =O / / -OCH3 ND 0.75 0.07
121 293.3 -C7H15 =O -F / -F 0.495 0.08 0.006
127 257.0 -C7H15 =O / / / ND 2.45 2.8
136 275.4 -C7H15 =O -F / / 2.634 0.02 0.13
271 411.0 -C13H8O2F3 =O / / / ND 2.75 5.6
300 475.8 -C13H8O2F3 =O / -Cl -OCH3 ND 0.33 25
316 459.4 -C13H8O2F3 =O / -F -OCH3 7.972 0.66 0.35
334 531.4 -C13H8O2F3 -O3C3H5 / -F -OCH3 5.81 3.33 ND
400 447.3 -C13H8O2F3 =O -F / -F 72.2 4
b 5
433 305.4 -C7H15 =O / -F -OCH3 ND 4.67 3.8
434 377.9 -C11H23 =O / -Cl -OCH3 ND 3.81 11
435 361.5 -C11H23 =O / -F -OCH3 ND 2.01 0.24
436 313.5 -C11H23 =O / / / ND 1.04 0.68
437 349.5 -C11H23 =O -F / -F ND 0.09 0.003
aResults reported in Anghel et al. (24); breported in Müller et al. (25); cresults reported in McConnell et al. (22), R, endochin core; ND, not done.
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TABLE 2 | Primary assessment of ELQ activities in terms of growth inhibition of B. besnoiti tachyzoites.
ELQ 100 121 127 136 271 300 316 334 400 433 434 435 436 437
%growth at 0.01µM 100 10 100 11 100 100 42 45 24 12 70 62 74 21
%growth at 0.1µM 93 0 10 0 21 67 12 7 0 5 ND 9 6 0
%growth at 1µM 3 0 0 0 1 8 5 0 0 0 25 8 0 0
Cultures were exposed to drugs at 0.01, 0.1, and 1µM during 3 days, and parasite proliferation was quantified by RT-PCR. ELQ-121, -136, -316, -334, and -400 (indicated in bold)
were selected for IC50 determinations. For information on the compound structures please refer to Table 1.
monolayers, the 10mM compound stock solutions, as well as
DMEM/10% FCS used for the dilution, were heated up to
37◦C to optimize compound solubility. Serial dilutions of the
compounds (1, 0.1, and 0.01µM, all in duplicate) were prepared
in DMEM and added to the confluent HFF monolayers. Controls
received DMSO diluted in culture medium corresponding
to the highest drug concentration. The medium containing
these serially diluted drugs were added to HFF monolayer,
and immediately thereafter cultures were infected with freshly
isolated Bb Lisbon tachyzoites (2.5 × 104 tachyzoites/well).
Infected cells were cultured at 37◦C, 5% CO2 for 3 days.
Subsequently, cells were collected with a cell scraper, centrifuged
and resuspended in 1ml PBS. DNA purification was performed
according the protocol of the MACHINERY-NAGEL Rapid Lyse
DNA isolation Kit. The DNA was eluted in 100 µl elution
buffer, and specimens were stored at −20◦C. Drug activity
assessments for each drug concentration were done in duplicate,
and each assay was done at least twice. B. besnoiti parasite
load was quantified by RT-PCR as described earlier (13). The
relative B. besnoiti growth values at the three drug concentrations
in relation to untreated control cultures are summarized in
Table 2.
Secondary Screening: Determination of the
Half-Minimal Inhibitory Concentration
(IC50)
The IC50 determinations for ELQ-121, -136, -316, -334, and
-400 in B. besnoiti infected HFF were done using the identical
setup as for the primary screening (see above). Culture media
containing compounds ELQ 121 and 136 were prepared at
the following concentrations: 50, 10, 5, 1, 0.5, 0.1, 0.05,
0.01, and 0.001 nM. Serial dilutions of the compounds ELQ-
316, -334, and -400 were done at 25, 5, 0.75, 0.25, 0.1,
0.05, 0.01, 0.005, and 0.001µM. Controls were devoid of
drug, but contained DMSO according to the highest drug
concentration used. After 3 days of treatment, cells were
collected with a cell scraper, centrifuged and resuspended
in 1ml PBS. DNA purification was done as described for
the primary screening, and samples were stored at −20◦C
prior to RT-PCR quantification of parasite load (9, 13). The
IC50 was determined by a logarithmic calculation (logit-
log) of the relative growth (RG), with growth in the non-
drug treated control set at 1. The logit-log-transformation
formula ln[RG/(1-RG)] = a × ln(drug concentration) + b was
accomplished and a subsequent regression analysis by an Excel
software “Analysis Tool Pack” package was done (Microsoft,
Seattle, WA).
Transmission Electron Microscopy (TEM)
Confluent HFF grown in T25 tissue culture flasks were infected
with 3 × 105 Bb-Lisbon tachyzoites, maintained for 48 h at
37◦C/5% CO2, treated with 2.5µM ELQ-121, -136, -316, or -334
during 6, 12, 24, and 48 h as indicated in the text, and were fixed
and processed for TEM analyses as previously described (13).
Briefly, medium was discarded, and monolayers were fixed in
5ml 2% glutaraldehyde in 0.1M Na-cacodylate buffer (fixation
solution) for 10min at room temperature (RT), and carefully
removed from the flask with a cell scraper. After centrifugation
(10min, 4◦C, 1,200 rpm), fresh fixation solution was added over
night at 4◦C. The samples were washed in 0.1M Na-Cacodylate-
buffer, and 1ml osmium tetroxide solution [2% in 0.1M
Na-Cacodylate buffer (pH 7.3)] was added for 1 h at RT. Samples
were washed 3× with water and 50 µl UranyLess solution
(ElectronMicroscopy Sciences, Hatfield, PA, USA) was added for
30min at RT. Subsequently, samples were washed in water and
were dehydrated by stepwise incubation in ethanol (30, 50, 70, 90,
and 3 x 100%). They were embedded in three changes of EPON-
812 resin, and polymerization was achieved at 60◦C overnight.
Ultrathin (80 nm) sections were cut using a Reichert and Jung
ultra-microtome (Vienna, Austria), and were loaded onto
300-mesh formvar-carbon coated grids (Plano GmbH, Marburg,
Germany). Finally, grids were contrasted using UranyLess and
lead citrate solutions (EMS) according to the manufacturer’s
instructions. Samples were viewed on a FEI Tecnai Spirit
BioTwin transmission electron microscope operating
at 80 kV.
Long-Term Treatment Assays
To investigate whether ELQs would affect an established
infection of B. besnoiti in HFF and whether the drug would
act parasiticidal or parasitostatic, long-term treatment assays
were performed as described earlier for N. caninum and T.
gondii (24, 28). Briefly, confluent HFF were infected with 5
× 105 tachyzoites for 4.5 h, washed two times with HBSS
(Hanks balanced salt solution), and were then exposed to 2.5µM
ELQ-121, -136, -316, or -334 for periods of either 3, 6, 9,
13, 15, 20, or 23 days, with medium changes and/or addition
of fresh compound-containing medium every 3 days. Once
the drug pressure was released, the cultures were inspected
daily for a period of 3 up to 23 days, and micrographs were
taken by light microscopy. In the case of ELQ-316, parasites
exposed to this compound for 20 days, followed by culture
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without compound for 10 days, were processed for TEM as
described above.
RESULTS
Primary in vitro Screening
For a preliminary efficacy assessment, B. besnoiti infected
HFF were exposed to the 14 ELQs at 1, 0.1, and 0.01µM.
Dose-dependent effects were seen for all compounds (Table 2).
Maximum growth inhibition (100%) at 0.1µM was observed for
ELQ-121, ELQ-136, ELQ-400 and ELQ-437. However, while at
0.01µM ELQ-437 and ELQ 400 treatments resulted in > 20%
relative growth, the respective growth values for ELQ-121 and
ELQ-136 were 10%, rendering those two drugs the most potent
inhibitors of B. besnoiti proliferation.
ELQ-121 and ELQ-136 were selected for further investigations
due to their potency in the primary screen. Based on previous
results on ELQ efficacy against T. gondii andN. caninum (18, 24),
we also selected ELQ-316 and its prodrug ELQ-334, as well as
ELQ-400, for further studies. ELQ-400 has been shown to exhibit
outstanding in vivo activity, better than atovaquone, in an acute
toxoplasmosis mouse model (22), and there is evidence that it
acts as a dual Qo and Qi site inhibitor (21).
IC50 Determinations
The IC50 values of ELQ-121, -136, -316, -334, and ELQ-400
are shown in Table 1, in comparison to those obtained for T.
gondii (22) and N. caninum (24). The lowest IC50 for B. besnoiti,
and the only one that was below 1 nM, was obtained with ELQ-
121 (0.49 nM) and for T. gondii and N. caninum, respective
values were also clearly below 1 nM, albeit by a factor of 10
(N. caninum) and 100 (T. gondii) lower. ELQ-136 had an IC50
value of 2.63 nM in B. besnoiti, which was roughly 163 and 20
times higher compared to reported values for N. caninum and
T. gondii, respectively. The IC50 value obtained for ELQ-316
(7.97 nM) was 12 and 22 times higher compared to N. caninum
and T. gondii, respectively, and the IC50 value for ELQ-334
(5.81 nM) was in the same range than the reported value in
N. caninum. The highest IC50 value, 72 nM, was measured for
ELQ-400. Overall, the IC50 values measured for B. besnoiti were
substantially higher than those previously reported for the closely
related apicomplexans N. caninum and T. gondii. For ELQ-334
we observed remarkable differences in IC50 values ranging from
2 to 82 nM (data not shown). The assays were repeated several
times, and we found that freshly prepared compound aliquots
(frozen and thawed not more than once) exhibited pronounced
higher activities compared to aliquots that were frozen and
thawed several times (IC50s 56.5–82.1 nM). This is possibly due
to crystallization and/or adherence to glass or plastic.
Sequence Alignment of Cytochrome b Qo
and Qi Sites of B. besnoiti and T. gondii
In order to investigate whether the differences in susceptibilities
of B. besnoiti tachyzoites to the different ELQs could be related
to differences in the putative cytochrome b Qo and Qi sites,
the corresponding sequences of the B. besnoiti cytochrome b
(Genbank Accession number PFH30612.1),T. gondii cytochrome
b (XP_018634734.1), and bovine (AAZ95348.1) and human
cytochrome b (UniProt P00156) were aligned according to
FIGURE 1 | Alignment of B. besnoitia, T. gondii, bovine (Bos Taurus), and human mitochondrial cytochrome b sequences representing the Qo and Qi binding sites.
Amino acids different in B. besnoiti and T. gondii are marked with an asterisk*, differences between T. gondii/B. besnoiti and Bos taurus are marked in blue, and the
differences between bovine and human sequences are indicated in red font.
Frontiers in Veterinary Science | www.frontiersin.org 5 February 2020 | Volume 7 | Article 96
Eberhard et al. ELQs and Besnoitia besnoiti
McConnell et al. (22) and compared (Figure 1). The Qo binding
site is identical in both parasite species, and the Qi site exhibits
only 3 amino acid (aa) variations with amino acids that are
similar to T. gondii. The B. besnoiti Qi site has a valine,
leucine, and serine at position 175, 179, and 200, respectively,
that correspond to isoleucine, isoleucine and threonine at the
analogous positions in the T. gondii cytochrome b. Amino acids
at these positions have not previously been found to influence
substrate or inhibitor binding (29). These subtle changes are very
unlikely to alter ELQ susceptibility. In addition, the B. besnoiti
cytochrome b is 97% identical to the T. gondii cytochrome b,
indicating that structural differences outside of the active sites
are also very unlikely to influence ELQ binding. However, in
comparison to the human enzyme, 18 aa variations are found
in the parasite Qo sites, all but one in the N-terminal half of
the binding site. More than 50 aa differences are found within
the Qi sites of B. besnoiti and T. gondii, when compared to
human and bovine cytochrome b Qi sites. These differences
include aa that are involved in substrate and inhibitor binding
and are likely determinants in ELQ specificity for apicomplexan
pathogens (29).
ELQ Treatments Induce Distinct
Ultrastructural Changes in B. besnoiti
Tachyzoites
Besnoitia besnoiti infectedHFFwere exposed to 2.5µMELQ-121,
-136, -316, and -334 for different time spans, ranging from 6 to
48 h, or cells were maintained as corresponding DMSO controls.
This concentration was chosen in order to exert a maximum
drug pressure against the parasite without impairing the host cell
integrity, similar to previous studies (24).
Parasites in control cultures exhibited typical apicomplexan
features (Figures 2A,B). The parasites were located
intracellularly within a parasitophorous vacuole surrounded by
a parasitophorous vacuole membrane (PVM), which separated
parasites from the host cell cytoplasm. The typical hallmarks of
apicomplexans, such as the apical complex including conoid,
micronemes, rhoptries, and dense granule, were clearly visible.
The single mitochondrion, parts of it visible in cross-sections,
exhibited a clearly discernible electron dense matrix.
Upon treatment with 2.5µM ELQ-136 and -121 for
6–12 h (Figures 2C,D), few alterations could be observed
compared to control cultures. The central parts of the
mitochondrial matrix became less electron dense in some
ELQ-136 treated parasites, but cristae structures remained
discernible (Figure 2C). However, the apical complex with
conoid and micronemes remained unaffected. After 12 h of
treatment with ELQ-121 (Figure 2D), the nuclear membrane
became slightly thickened, widening the gap between nucleus
and the surrounding cytoplasm. After 24 h ELQ-121 treatment
(Figure 2E), the mitochondrion also started to exhibit distinct
alterations, such as the loss of an electron dense matrix
and associated cristae. In addition, as shown for ELQ-121 in
Figure 2F, the entire nuclear membrane appeared thickened
in many cells, and the number of cytoplasmic vesicles was
increased. However, no further ultrastructural changes were
evident, thus the typical apicomplexan secretory organelles such
as rhoptries, micronemes, and dense granules, and the parasite
plasma membrane and conoid, remained clearly discernible.
Upon treatment with 2.5µM ELQ-316 (Figures 3A–C) for
6–12 h, alterations within the mitochondrion were also evident.
The mitochondrial matrix became less electron dense already
after 6 h. Like the other compounds, the drug also altered the
spacing between the nucleus and cytoplasm, and vacuolization
of the cytoplasm occurred after 6 h of treatment (Figure 3A).
The apical complex with conoid and micronemes was not
notably affected. Upon treatment with 2.5µM ELQ-316 for
24 and 48 h (Figures 3B,C), alterations of the mitochondrion
and vacuolization of the cytoplasmic were maintained. Other
structures, however, remained unaffected. Exposure of B. besnoiti
to 2.5µM ELQ-334 for a time period of 12–24 h showed less
pronounced alterations within the mitochondrion, and the
apical complex and associated secretory organelles did not
seem to be affected (Figures 3D,E). Upon ELQ-334 treatment
over 48 h (Figure 3F), alterations in the mitochondrion
became more evident, and cytoplasmic vacuolization
clearly increased.
Overall, ELQ treatments most notably affected the tachyzoite
mitochondrion by altering the electron dense matrix and
cristae to the extent that the organelle, although exhibiting
an intact mitochondrial membrane, appeared either devoid
of content, or contained undefined residual structures
of unknown composition. In general, parasites retained
their shape and were still located inside a parasitophorous
vacuole, surrounded by a PVM. The most clear and rapid
mitochondrial alterations were found upon treatment
with ELQ-136 and ELQ-316 (already at 6 h), whereas
the treatment with its prodrug ELQ-334 changed the
mitochondrial ultrastructure only after 24–48 h, most likely
reflecting the time it takes for ELQ-334 to be converted
to ELQ-316.
Long-Term Treatments Reveal
Parasitostatic Rather Than Parasiticidal
Activities of ELQs
Results on long-term treatment assays are documented for ELQ-
121, ELQ-136 and -334 in Table 3, and are visualized for ELQ-
136 in Figure 4. In the control cultures supplemented with
the appropriate concentration of DMSO as a solvent control,
B. besnoiti tachyzoites proliferated rapidly and the host cell
layer was destroyed after 3–4 days post-infection. In ELQ
treated cultures, parasite growth was much delayed, regardless
which drug was used. Until day 3 of treatment, few large
parasitophorous vacuoles developed. More often, small vacuoles
could be observed and few extracellular parasites could be seen.
Removing the drug pressure 3 days after a continued treatment,
resulted in increased proliferation and finally complete lysis of
the host cell layers within 17 days post-drug removal in the case
of ELQ-121, 16 days for ELQ-136 (see Figure 4) and 10 days
for ELQ-334. Continued treatment for 13 days resulted in lysis
of the entire host cell monolayer at 21 days after drug removal
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FIGURE 2 | TEM of non-treated B. besnoiti tachyzoites cultured in human foreskin fibroblasts devoid of drugs at 48 h post-infection (A,B). Tachyoites maintained in
the presence of 2.5µM ELQ-136 during 6 h are shown in (C), parasites treated with ELQ-121 during 12, 24 and 48 h are shown in (D–F), respectively. Encircled areas
indicate the mitochondrion, white arrows point toward a thickening of the nuclear membrane; v, vacuole; nuc, nucleus; dg, dense granules; rhop, rhoptries; pvm,
parasitophorous vacuole membrane; mic, micronemes; con, conoid. Bar in (A) = 500 nm; (B,C) = 300 nm; (D) = 400 nm; (E,F) = 300 nm.
for ELQ-121, at 14 days for ELQ-136 and at 10 days for ELQ-
334. Even after the maximum period of treatment for 23 days,
parasites recovered from the treatment and proliferated again
after drug pressure removal, and complete host cell lysis was
achieved 18 days after drug removal for ELQ-121, and 10 days
for ELQ-136.
Thus, after an initial inhibition of proliferation, B. besnoiti
tachyzoites exhibited the capacity to efficiently adapt to
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FIGURE 3 | TEM of B. besnoiti infected HFF exposed to 2.5µM ELQ-316 during 6, 24, and 48 h (A–C), and ELQ-334 during 12, 24, and 48 h, respectively. The
encircled areas indicate the mitochondrion, arrows indicate a thickening of the nuclear membrane; nuc, nucleus; dg, dense granules; rhop, rhoptries; mito,
mitochondrion; PVM, parasitophorous vacuole membrane; mic, micronemes; con, conoid. Bars in (A,B) = 400 nm; (C) = 350 nm; (D) = 500 nm; (E,F) = 300 nm.
prolonged treatments at increased ELQ concentrations. In order
to investigate whether this adaptation would also result in
morphological or structural alterations, B. besnoiti cultures that
had been treated with 2.5µM ELQ-136 during 20 days and then
further cultured inmediumwithout drug, were subjected to TEM
analysis (Figure 5). Many parasites in these cultures exhibited
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T25 tissue culture flasks were infected with B. besnoiti tachyzoites, and the compounds
were added all at 2.5µM concentration. Culture continued for the time spans indicated,
with medium changes and addition of fresh compounds every 3–4 days. The cultures
were then washed with medium to remove the drugs and then incubated further in the
absence of the compounds until host cell lysis occurred. ND, not done.
peculiar structural changes. A large portion of parasites formed
large amorphous bodies within their cytoplasm, which closely
resembled amylopectin granules (Figures 5A,B). Amylopectin
granules are often seen in the bradyzoites of cyst-forming
apicomplexans. In addition, major parts of the cytoplasm were
vacuolized, and no intact mitochondrion could be detected
in these parasites, indicating that these vacuoles were derived
from degeneratedmitochondria. Other parasitophorous vacuoles
contained multiple parasites devoid of amylopectin granules
(Figure 5C), but with altered thickened nuclear membrane
and larger vacuoles, also most likely mitochondrial remnants.
No intact mitochondrial structures could be visualized in
these parasites.
DISCUSSION
We here report on the in vitro efficacy of distinct ELQ-analogs
against B. besnoiti tachyzoites. ELQs act on the cytochrome bc1
complex. At the oxidative (Qo) site of cytochrome b, ubiquinol
is oxidized to ubiquinone by releasing two electrons and two
protons, and at the reductive (Qi) binding site, ubiquinone is
reduced to ubiquinol (30). Blocking only one Q site, either Qo
or Qi, results in an inhibition of the catalytic functioning of the
complex, which leads to a collapse of the electrochemical gradient
and oxidative phosphorylation, or in the case of Plasmodium,
pyrimidine starvation due to a lack of ubiquinone for its
biosynthesis. The scaffold of 4(1H)-quinolone is compatible with
binding at either the Qo or Qi site and depending on the
quinolone core substituents. Dual-site inhibition of cytochrome
b is favorable in terms of resistance formation, as this would
require two independent mutations within the same protein
target appearing at the same time (31).
Fourteen ELQs with side chain variations coupled with
Q-site targeting substituents were screened. These had been
previously generated to test structure-activity relationships of
Qi vs. Qo site selectivity in Plasmodium and Toxoplasma (20,
22). The compounds have different alterations, such as an alkyl
or diphenyl ether side chain at the third position and several
substitutions at positions 4, 5, 6, or 7 of the endochin ring.
The primary screening showed (i) that quinolones containing
fluorine atoms at position 5 or 5,7 in combination with a
3-alkyl side chain are the most active compounds against B.
besnoiti tachyzoites in vitro, and (ii) that B. besnoiti tachyzoites
were generally less susceptible to ELQ treatment compared to
the closely related N. caninum and T. gondii. Five compounds
were selected for determination of IC50 values by quantitative
real time PCR. In 3-days proliferation assays, ELQ-316 and its
prodrug ELQ-334 inhibited B. besnoiti tachyzoite proliferation
with IC50s of 7.97 and 5.81 nM, respectively. In comparison,
the IC50 values against N. caninum tachyzoites for ELQ-
316 and ELQ-334 were 0.66 and 3.33 nM, respectively. Oral
administration of ELQ-334 led to improved pup survival and
inhibition of vertical transmission in a pregnant neosporosis
mouse model (24). The IC50 value of ELQ-316 against T. gondii
tachyzoites was in the same range as N. caninum (0.35 nM), and
experiments in murine toxoplasmosis models have shown that
ELQ-316 was highly efficacious in acute infection mediated by
T. gondii tachyzoites, and also reduced the tissue cysts burden in
vivo in a latent toxoplasmosis infection model (18). The lowest
IC50 values in B. besnoiti were demonstrated for ELQ-121 and
ELQ-136, with 0.49 and 2.63 nM, respectively. Nevertheless, the
IC50 of ELQ-121 was roughly 5 and 80 times higher than the
reported IC50 values for N. caninum and T. gondii, and the IC50
of ELQ-136 was 130 and 20 times higher, respectively (22, 24).
Another compound of interest was ELQ-400, which was
identified earlier as an active compound against N. caninum
infection through a screening of the MMV (medicines for
malaria venture) pathogen box (25). In N. caninum, ELQ-400
exhibited an IC50 value that was similar to ELQ 334, inhibited
both host cell invasion and intracellular proliferation of N.
caninum tachyzoites in vitro, and induced strong alterations in
the parasite mitochondrion (25). However, ELQ-400 was more
efficient than ELQ-334 in preventing cerebral infection in non-
pregnant mice. The higher activity of ELQ-400 in N. caninum,
in comparison to other ELQs, may be due to pharmacokinetics
(21, 22). However, in B. besnoiti, ELQ-400 exhibited an in
vitro IC50 of 72.2 nM, which is ∼18 times higher than the
reported value for N. caninum. Possible causes for the observed
discrepancies in activities among the three apicomplexans could
be differential uptake of drugs in different species, and off-
target effects that occur in one species but not in the other.
These effects may result in an additive or synergistic activity in
concert with cytochrome bc1 inhibition (22, 29). In addition, the
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FIGURE 4 | ELQ-136 long-term treatment assay. 2.5µM of ELQ-136 was administered from 3 days until 23 days as indicated on the left. Drug pressure was
released, and cells were kept in culture with medium for extended periods of time (3–18 days). Note that regrowth of parasites was seen in all cases.
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FIGURE 5 | TEM of B. besnoiti tachyzoites treated with 2.5µM of ELQ-316 during 20 days, and then cultured without drug during 10 days. The encircled areas
indicate the mitochondrion, arrows point to a thickening of the nuclear membrane; nuc, nucleus; dg, dense granules; rhop, rhoptries; mic, micronemes; apg,
amylopectin granules. Bars in (A) = 500 nm; (B) = 200 nm; (C) = 350 nm.
use of different isolates and host cell lines, culture conditions
and methods of quantification could be attributed to different
IC50 values.
Discrepancies in drug susceptibilities could potentially also be
based on slight variations in the molecular target sequences that
affect ELQ binding. In this respect, we identified no sequence
divergence among T. gondii and B. besnoiti in the predicted Qo
binding pockets and only 3 aa acid substitutions that differed in
the T. gondii and B. besnoiti Qi sites, two in the D-Helix and
one in the de Loop region of the Qi site. To what extent, these
differences affect the interactions with the ELQs investigated here
is not known. The different substitutions in the structure of the
ELQs are responsible for the activity and the differential binding
of the drug to either the Qi site, the Qo site, or both sites (20).
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Thus, SAR analysis showed that ELQ-121 and ELQ-136 target the
cytochrome bQo site whereas ELQ-316 targets the cytochrome b
Qi site of the complex (22).
The almost complete identity of sequences of the Qi and
Qo binding pockets of T. gondii and B. besnoiti indicates
that ELQs target the cytochrome bc1 complex of B. besnoiti.
TEM showed that during the treatment of B. besnoiti and N.
caninum tachyzoites with ELQs, the parasite mitochondrion
clearly lost its characteristic electron dense matrix with visible
cristae. Interfering with the electron transport chain of the
mitochondrion causes the release of electrons, which possibly can
relocate to other biomolecules. This might result in an induction
of free radicals and ROS, which are harmful for the parasite.
Thus, it appears that a strategy of this parasite to avoid these
adverse effects is to get rid of a structurally intact mitochondrion,
and switch from oxidative phosphorylation to glycolysis. The
intermediate metabolites needed for glycolysis would then have
to be scavenged from the host cell.
Indeed, B. besnoiti tachyzoites exhibited structural changes
in their mitochondrial matrix already after 6 h of treatment,
and these changes became progressively more obvious at later
timepoints for all compounds investigated. In addition to
the mitochondrial alterations, TEM also detected a gradual
thickening of the nuclear membrane, the integrity of which was
altered in the drug-treated parasites compared to the untreated
specimens as it appeared partially separated, creating a wider
distance between nucleus and surrounding cytoplasm. Such a
compartmentalization of the cytoplasm could possibly be an
effect of autophagy upon chronic mitochondrial respiratory
chain impairment (32). However, this needs to be further
investigated. Also, while there is clear evidence that ELQs
are targeting the ubiquinone binding site of the cytochrome
bc1 complex, it should be considered, that there is also non-
mitochondrial ubiquinol, and there are potential ELQ binding
sites outside the mitochondrion that might be targeted by
these compounds. For instance ubiquinone also contributes to
electron transport as a transmembrane component of the Golgi
apparatus (33).
While these changes within the first 48 h of drug treatment
appeared dramatic, we found that B. besnoiti tachyzoites
exhibited an outstanding adaptive potential, in that after
continuous treatment for 20 days they had survived and resumed
proliferation, albeit at a slower rate. Visualization of these
parasites by TEM revealed that they had adopted profound
structural alterations. In many instances, the cytoplasm of treated
and recovered parasites was filled with round amorphous bodies
that closely resembled amylopectin granules normally found in
bradyzoites. Amylopectin granules were also identified in B.
besnoiti tachyzoites treated with several bumped kinase inhibitors
(BKIs) (11), nitazoxanide (9), pentamidine derivatives (10),
and in Besnoitia treated with another cytochrome bc1 complex
inhibitor, the naphtoquinone buparvaquone (13). Thus, these
features are most likely associated with general physiological
stress and potentially with metabolic adaptation rather than
being specific indicators of the mechanism of action of these
compounds. Interestingly, also upon prolonged buparvaquone
treatment, B. besnoiti has been shown to adapt to increased
concentrations of buparvaquone, and buparvaquone-adapted B.
besnoiti also lacked a mitochondrion with an electron dense
matrix and discernible cristae (13). It thus appears that a
structurally intact mitochondrion is not a prerequisite for
parasite survival, pointing toward alternative metabolic pathways
beside oxidative phosphorylation for generating energy, such
as glycolysis, and possibly increased scavenging of essential
metabolites from the host cell.
In future investigations, drug combination approaches could
be considered. A combination of the prodrug ELQ-334, a Qi
site inhibitor, with a Qo site inhibitor may have higher activity
and increased efficacy due to the dual site inhibition effect.
This was achieved for the treatment of Babesia microti, where a
combination of ELQ-334 and atovaquone resulted in a radical
cure (31). The availability of well-established and standardized
experimental in vivo models for bovine besnoitiosis would be
an important prerequisite to carry out such studies in the target
host (2).
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